Answer
Yes. Ponatinib inhibits T315I-mutant BCR-ABL, and the mutation is specifically included in its licensed indications.
Sources for this answer
- Ponatinib Incyte 15 mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.